Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | BTK | Q06187 | 10/20 | 0.38 |
| ▸ | TGM2 | P21980 | 2/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30736122 | 0.86 | CSNK1E (0.37) | BTK | |
| SCHEMBL30791524 | 0.84 | BTK (0.47) | EGFRBTK | |
| SCHEMBL25714798 | 0.83 | BTK (0.46) | EGFRBTK | |
| SCHEMBL31745485 | 0.80 | BTK (0.42) | EGFRBTKTGM2F13A1TGM1 | |
| SCHEMBL29002681 | 0.79 | MAP2K7 (0.41) | EGFRBTKTGM2F13A1TGM1 | |
| SCHEMBL29002661 | 0.79 | BTK (0.42) | EGFRBTKTGM2MAP2K7 | |
| SCHEMBL31745484 | 0.79 | BTK (0.41) | EGFRBTKTGM2F13A1TGM1 | |
| SCHEMBL31745489 | 0.79 | BTK (0.41) | EGFRBTKTGM2MAP2K7 | |
| SCHEMBL31745444 | 0.79 | BTK (0.41) | EGFRBTKTGM2MAP2K7 | |
| SCHEMBL31745486 | 0.79 | BTK (0.40) | EGFRBTKTGM2MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
| EP-4547669-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024002157-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | EGFR 17/4885BTK 178/4885TGM2 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.